Annual report pursuant to Section 13 and 15(d)

Organization and Basis of Presentation (Details Narrative)

v3.22.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 17, 2021
Dec. 31, 2021
Dec. 31, 2020
Accumulated deficit   $ (36,000,000)  
Common Stock Exercise Price $ 7    
Net Cash Used In Operation   $ 5,700,000 $ 4,000,000
Combined Offering Price 7    
Sale of stock 2,571,428    
Warrants to purchase one share of common stock 2,957,142    
Conversion of stock 65,823,015    
Common stock outstanding   8,328,629  
Warrant exercise price   $ 7  
Conversion of stock amount   $ 6,582 $ 0
Convertible Notes [Member]      
Conversion of stock 32,219    
Accrued interest $ 5,434    
Conversion of stock amount $ 175,000    
Initial Public Offering [Member]      
Combined Offering Price 7    
Sale of stock 2,571,428    
Warrants to purchase one share of common stock 2,571,428    
Common stock outstanding 1,911,009    
Warrant exercise price $ 7    
Incremental number of warrants issued at IPO 385,714    
Option exercise price $ 7    
Gross Proceeds from warrants purchase of common stock $ 15,400,000    
Issuance costs $ 2,600,000    
Common Stock [Member]      
Conversion of stock 3,813,973    
Series 1a Preferred Stock      
Conversion of stock 1,419,228    
Warrants exercisable into common stock 69,212